Drug Trial Radar · NCT04410965
Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
May 20, 2020
Primary completion
Jul 12, 2021
Study completion Jul 12, 2021
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: Evaluate the relationship between ABCG2 mutation (rs2231142) and teriflunomide exposure, during 6-month treatment with teriflunomide 14 mg Secondary Objective: Characterize the safety (AEs, such as ALT enhancement, hair thinning, diarrhea, nausea, etc.) during 6-month treatment with teriflunomide
Conditions
- Multiple Sclerosis
Interventions
TERIFLUNOMIDEDrug
Pharmaceutical form:tablet Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK exposure: CmaxTime frame: From Week 8 to Week 24
- PK exposure: AUCtauTime frame: From Week 8 to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational Site Number
China, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.